Aesthetic Breast Surgery Updates
On this page you can find the latest updates relating to aesthetic breast surgery
In June 2019 Jones et al published a paper in Histopathology entitled Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathologic diagnosis and management
NHS Improvements have produced a patient information leaflet, Evidence Based Interventions: Surgery for Breast Reduction
The FDA have released a statement on breast implants following their recent public advisory committee meeting held in March 2019. This is available here for information.
There are a growing number of women who believe that they have a condition, which they have called Breast Implant Illness. This condition consists of a very broad range of non-specific symptoms such as hair loss, brain fog, general fatigue, fibromyalgia, ME, irritable bowel syndrome, skin conditions, lupus, rheumatoid, SLE, Reynaud’s.
ABS members will be aware that the CE mark for Allergan Biocell textured implants has recently not been reinstated. A sample letter [updated November 2019] is available, which members may wish to use when responding to patients, who have implants in situ, to give them further information.
ABS, BAPRAS and the British Society of Breast Radiology have collaborated to produce these guidelines to help surgeons manage patients before and after aesthetic breast procedure. The guidance is based on review of published evidence and, where this is available, a consensus between imaging and surgical specialists. The guidance pertains to all aspects of aesthetic surgery.
To view the guidance please click here